Inhibiting transcriptional mechanisms of resistance via CBP/p300 represents an exciting and much needed opportunity for more effective and tolerable therapies. TT125-802 has shown impressive ...

Inhibiting transcriptional mechanisms of resistance via CBP/p300 represents an exciting and much needed opportunity for more effective and tolerable therapies. TT125-802 has shown impressive activity ...

Got an artistic project that you want to bring to life? You're in luck—the De La Salle-College of Saint Benilde is offering a production grant to help make your potential masterpiece a reality. The ...

When integrated with the Virtuora Network Control portfolio, the 1FINITY P300 simplifies the planning, design, and deployment of multi-domain, multi-vendor optical and packet-optical networks, ...

Preclinical data demonstrate that inhibiting the p300 KAT domain reactivates p53 in HPV-driven tumors resulting in anti-tumor activity – SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE ...

Recently published in eBioMedicine, Zhang et al. reported the first peptide-based PROTAC targeting p300 via its CH1 domain. 10 Peptide drugs offer advantages in increased specificity and efficacy due ...

In a recent study, researchers from Technische Universität Dresden and affiliated organizations evaluated the novel small-molecule inhibitor of the CBP/p300 HAT domain, A-485, as a potential ...

In this case, this domain might be druggable to produce "leukocytosis on demand" by altering the sizes of different leukocyte compartments. The scientists found that inhibiting the CBP/p300 domain ...

New development candidate, KB-9558 Kronos Bio’s new development candidate, KB-9558, targets the KAT domain of p300, a critical node of the IRF4 TRN, which is a core oncogenic transcription ...

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New ...